Mallinckrodt Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MALLINCKRODT, and what generic alternatives to MALLINCKRODT drugs are available?
MALLINCKRODT has forty-six approved drugs.
There are thirty-three US patents protecting MALLINCKRODT drugs.
There are one hundred and sixty-one patent family members on MALLINCKRODT drugs in twenty-two countries and seventy-eight supplementary protection certificates in eight countries.
Summary for Mallinckrodt
International Patents: | 161 |
US Patents: | 33 |
Tradenames: | 39 |
Ingredients: | 29 |
NDAs: | 46 |
Patent Litigation for Mallinckrodt: | See patent lawsuits for Mallinckrodt |
PTAB Cases with Mallinckrodt as patent owner: | See PTAB cases with Mallinckrodt as patent owner |
Drugs and US Patents for Mallinckrodt
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mallinckrodt | PERCHLORACAP | potassium perchlorate | CAPSULE;ORAL | 017551-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Mallinckrodt | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | acetaminophen; hydrocodone bitartrate | TABLET;ORAL | 040084-003 | Jul 29, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-003 | Dec 23, 1999 | AA | RX | Yes | Yes | 8,776,794*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Mallinckrodt | OXYCODONE AND ACETAMINOPHEN | acetaminophen; oxycodone hydrochloride | TABLET;ORAL | 040550-001 | Jun 30, 2004 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mallinckrodt
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-002 | Dec 23, 1999 | 5,732,693*PED | ⤷ Try a Trial |
Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-002 | Dec 23, 1999 | 5,752,504*PED | ⤷ Try a Trial |
Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | 4,845,075 | ⤷ Try a Trial |
Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-002 | Dec 23, 1999 | 5,873,359*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MALLINCKRODT drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 1000 mg/100 mL (10 mg/mL) | ➤ Subscribe | 2011-04-07 |
➤ Subscribe | for Inhalation | 100 ppm and 800 ppm | ➤ Subscribe | 2014-05-20 |
➤ Subscribe | Extended-release Tablets | 7.5 mg/325 mg | ➤ Subscribe | 2014-04-03 |
Premature patent expirations for MALLINCKRODT
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Try a Trial | ⤷ Try a Trial |
International Patents for Mallinckrodt Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2905644 | ⤷ Try a Trial |
China | 114028536 | ⤷ Try a Trial |
Japan | 2005507000 | ⤷ Try a Trial |
Japan | 2017507329 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mallinckrodt Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0268956 | SPC/GB98/040 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508 |
1948158 | 1690020-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
1856135 | CR 2020 00018 | Denmark | ⤷ Try a Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
0957929 | SPC/GB06/021 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.